Scientific Reports,
Journal Year:
2025,
Volume and Issue:
15(1)
Published: Feb. 4, 2025
Colorectal
cancer
(CRC)
is
a
serious
public
health
concern
worldwide.
Immune
checkpoint
inhibition
medication
likely
to
remain
crucial
part
of
CRC
clinical
management.
This
study
aims
create
new
super
paramagnetic
iron
oxide
nano-carrier
(SPION)
that
can
effectively
transport
miRNA
specific
cell
lines.
In
addition,
evaluate
the
efficiency
this
nano-formulation
as
therapeutic
candidate
for
CRC.
Bioinformatics
tools
were
used
select
promising
tumor
suppressor
(mir-497-5p).
Green
route,
using
Fusarium
oxyporium
fungal
species,
manipulated
synthesis
SPION@Ag@Cs
nanocomposite
carrier
miR-497-5p.
That
specifically
targets
suppression
PD1/PDL1
and
CTLA4pathways
colorectal
therapy.
UV/visible
FTIR
spectroscopy,
Zeta
potential
MTT
confirm
allocation
miR-497
on
its
cytotoxicity
against
Immunofluorescence
was
employed
transfection
cells
with
miR-497@NPs,
down-
regulation
CTLA4
in
HT29,
Caco2
On
other
hand,
PDL1
showed
significant
increase
lines
(HT-29
Caco-2)
response
mir497-5p@Nano
treatment.
The
data
suggest
mir-497
-loaded
could
be
good
CTLA4in
human
Consequently,
targeting
miR-497/CTLA4
axis
immunotherapy
treatment
strategy
Materials Technology,
Journal Year:
2025,
Volume and Issue:
40(1)
Published: March 21, 2025
Oral
pathogen
biofilms
contribute
to
chronic
infections,
while
oral
cancer
remains
a
significant
health
threat,
emphasizing
the
need
for
effective
therapeutic
strategies.
This
study
investigates
fabrication,
characterization,
and
potential
of
copper
oxide-stigmasterol
nanoparticles
(CuO-SS
NPs)
biofilm
disruption
treatment.
The
antimicrobial
activity
CuO-SS
NPs
was
evaluated
against
pathogens,
including
S.
aureus,
mutans,
E.
faecalis,
C.
albicans.
In
cell
studies,
exhibited
concentration-dependent
cytotoxicity,
reducing
viability
from
88%
at
15
µg/mL
29.33%
120
µg/mL,
comparable
doxorubicin
(24.3%).
significantly
upregulated
apoptosis
markers
(Caspase-3,
Caspase-8,
FasL)
by
4.05,
1.4,
3.1
fold,
respectively.
These
results
highlight
as
dual-purpose
infections
cancer.